{"id":109002,"date":"2025-04-03T04:12:00","date_gmt":"2025-04-03T07:12:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/boehringer-ingelheim-strengthens-antibody-drug-conjugate-portfolio-with-new-nbe-therapeutics-rd-center-in-basel\/"},"modified":"2025-04-03T04:12:00","modified_gmt":"2025-04-03T07:12:00","slug":"boehringer-ingelheim-strengthens-antibody-drug-conjugate-portfolio-with-new-nbe-therapeutics-rd-center-in-basel","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/boehringer-ingelheim-strengthens-antibody-drug-conjugate-portfolio-with-new-nbe-therapeutics-rd-center-in-basel\/","title":{"rendered":"Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&amp;D center in Basel"},"content":{"rendered":"<div>\n<div>\n<ul role=\"list\">\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"25\" data-aria-posinset=\"1\" data-aria-level=\"1\" role=\"listitem\">\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>CHF <\/span><span>27 million i<\/span><span>nvestment signi<\/span><span>ficantly bolsters <\/span><span>Boehringer&#8217;s ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the companys aim of transforming the lives of people with cancer<\/span><span>.<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul role=\"list\">\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"25\" data-aria-posinset=\"2\" data-aria-level=\"1\" role=\"listitem\">\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Boehringer Ingelheim strengthens <\/span><span>footprint<\/span><span> <\/span><span>in Swiss <\/span><span>b<\/span><span>iotech <\/span><span>i<\/span><span>nnovation <\/span><span>hub<\/span><span>.<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/li>\n<\/ul>\n<\/div>\n<div>\n<p><strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Basel, Switzerland, T<\/span><span>hurs<\/span><span>day, 0<\/span><span>3<\/span><span>.04.2025<\/span><span> <\/span><\/span><\/strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span> <\/span><span>Today <\/span><span>NBE<\/span><span> <\/span><span>Therapeutics<\/span><span> (NBE<\/span><span>)<\/span><span> <\/span><span>a <\/span><span>wholly owned <\/span><span>subsidiary of<\/span><\/span><span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>\u00a0<\/span><\/span><\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span> <\/span><span>Boehringer Ingelheim<\/span><span>,<\/span><span> <\/span><span>officially opened<\/span><span> <\/span><span>its new <\/span><\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>ADC R&amp;D <\/span><span>facility<\/span><\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span> <\/span><span>in Basel<\/span><span>. This milestone<\/span><span> reinforc<\/span><span>es<\/span><span> its commitment to innovation in oncology and strengthen<\/span><span>s<\/span><span> its footprint in Switzerlands biotech ecosystem.<\/span><span> <\/span><span>NBE<\/span><span> <\/span><span>Therapeutics, a <\/span><span>Swiss <\/span><span>biotech<\/span><span> founded in 2012<\/span><span> that became part of Boehringer Ingelheim in 2020, plays a pivotal role in the companys oncology research strategy<\/span><span>.<\/span><span> <\/span><span>The <\/span><span>new<\/span><span> <\/span><span>facility<\/span><span> will serve as a <\/span><span>leading research center<\/span><span> for advancing <\/span><span>antibody-drug conjugates (<\/span><span>ADC<\/span><span>)<\/span><span> research and development, supporting Boehringer Ingelheims commitment <\/span><span>to<\/span><span> developing transformative cancer therapies to improve patient<\/span><span>s<\/span><span> lives <\/span><span>globally<\/span><span>.\u00a0<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Advancing ADC research with <\/span><span>investment in <\/span><span>Swiss <\/span><span>NBE <\/span><span>Therapeutics<\/span><span> site<\/span><\/span><span>\u00a0<\/span><\/strong><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>This <\/span><span>investment <\/span><span>in <\/span><span>NBEs <\/span><span>Basel site<\/span><span> is a significant step toward Boehringer Ingelheims goal of transforming cancer care. It bolsters <\/span><span>our <\/span><span>robust oncology pipeline<\/span><span> and adds <\/span><span>on top of <\/span><span>a<\/span><span> recent <\/span><span>license agreement with <\/span><span>Synaffix<\/span><span> B.V., Amsterdam,<\/span><span> <\/span><span>expanding <\/span><span>NBE<\/span><span><\/span><span>s <\/span><span>ADC <\/span><span>portfolio<\/span><span> and <\/span><span>the recent opening of a new <\/span><span>facility at our <\/span><span>oncology <\/span><span>research <\/span><span>site <\/span><span>in Vienna, Austria<\/span><span>. <\/span><span>The new <\/span><span>research <\/span><span>facility <\/span><span>will <\/span><span>contribut<\/span><span>e<\/span><span> to<\/span><span> <\/span><span>building <\/span><span>a broad pipeline of ADCs<\/span><span>,<\/span><span> addressing novel tumor target space to develop next-generation cancer treatments.<\/span><span>\u00a0<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>NBE <\/span><span>Therapeutics focuses on developing next-generation ADCs, a targeted approach that delivers cancer-fighting agents directly to tumor cells while limiting effects on healthy tissue. ADCs combine the specificity of <\/span><span>antibodies<\/span><span> with the therapeutic <\/span><span>activity<\/span><span> <\/span><span>of <\/span><span>cytotoxics<\/span><span>, offering a promising <\/span><span>option<\/span><span> for cancer treatment to improve the quality of life for patients.\u00a0<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"none\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>&#8220;This investment in <\/span><span>a<\/span><span> <\/span><span>new<\/span><span>, <\/span><span>cutting-edge<\/span><span> research center<\/span><span> <\/span><span>underscores our strong <\/span><span>commitment<\/span><span> <\/span><span>to <\/span><span>deliver <\/span><span>breakthrough innovation to <\/span><span>people living with cancer<\/span><span>,&#8221; said <\/span><\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Jean Engela, <\/span><span>CEO<\/span><\/span><span data-contrast=\"none\" xml:lang=\"EN-US\" lang=\"EN-US\"><span> at <\/span><span>NBE <\/span><span>Therapeutics. &#8220;We are confident that this state-of-the-art building will enable our team <\/span><span>of scientists <\/span><span>to <\/span><span>accelerate <\/span><span>the development of next-generation ADCs, ultimately impacting the lives of patients battling cancer.&#8221;<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>The new <\/span><span>facility <\/span><span>represents<\/span><span> an <\/span><span>additional<\/span><span> commitment of CHF 27 million <\/span><span>in<\/span><span> ADC R&amp;D over several years<\/span><span>. <\/span><span>It<\/span><span> will provide a <\/span><span>sophisticated<\/span><span> research environment to accelerate the development of innovative ADC therapies<\/span><span>,<\/span><span> while fostering synergies through access to a broad pool of scientists and experts within the global Boehringer Ingelheim oncology network.<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>A commitment to innovation and sustainability<\/span><\/span><span>\u00a0<\/span><\/strong><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Switzerland offers an unparalleled biotech ecosystem. By strengthening our presence here, we are reinforcing our commitment to advancing innovative cancer treatments, said<\/span><span> Karl Penz, CFO of the Innovation Unit at Boehringer Ingelheim and Chairperson of the NBE Therapeutics Board of Directors<\/span><span>.<\/span><\/span><span> <\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span \/><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Kaspar Sutter, Head of Department of Economic, Social and Environmental Affairs of the Canton of Basel-Stadt; Member of the Government <\/span><span>said: <\/span><span>As the Government of Basel-Stadt we want to provide a good environment for companies to prosper, particularly in the life sciences field. The development of NBE Therapeutics is a success story and it has been a privilege to <\/span><span>accompany<\/span><span> and support NBE Therapeutics on this journey from the very beginning, starting at the Tech Park Basel. We very much appreciate this significant investment by NBE Therapeutics and the strong commitment of Boehringer Ingelheim to the Basel Area.<\/span><span><\/span><\/span><span> <\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span \/><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>The new <\/span><span>R&amp;D center<\/span><span> <\/span><span>meets the highest <\/span><span>Swiss <\/span><span>sustainability standards<\/span><span> and has been<\/span><span> awarded the <\/span><span>DGNB <\/span><span>Certificate<\/span><span> Gold<\/span><span> by <\/span><span>the <\/span><span>Schweizer Gesellschaft f\u00fcr <\/span><span>Nachhaltige<\/span><span> <\/span><span>Immobilienwirtschaft<\/span><span> (<\/span><span>SGNI<\/span><span>)<\/span><span>. <\/span><span>This certification is based on criteria developed by the <\/span><\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Deutsche<\/span><span> <\/span><span>Gesellschaft f\u00fcr <\/span><span>Nachhaltiges<\/span><span> <\/span><span>Bauen<\/span><\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span> (DGNB).<\/span><span> <\/span><span>Featuring energy-efficient design and responsibly sourced materials, it provides<\/span><span> 1<\/span><span>,<\/span><span>826 m<\/span><\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span data-fontsize=\"10\">2<\/span><\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span> <\/span><span>of <\/span><span>lab<\/span><span>oratories<\/span><span> and office space<\/span><span>, enabling seamless collaboration with the extensive global network of Boehringer Ingelheim. <\/span><span>The building will serve as a<\/span><span>n<\/span><span> <\/span><span>inspiring <\/span><span>workplace<\/span><span> <\/span><span>for <\/span><span>a team of <\/span><span>approximately <\/span><span>50\u00a0 scientists<\/span><span>, in addition to various support<\/span><span>ing<\/span><span> <\/span><span>functions, including HR, <\/span><span>administration<\/span><span> a<\/span><span>nd management<\/span><span>.<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Boehringer Ingelheim <\/span><span>f<\/span><span>ootprint in Switzerland<\/span><\/span><span>\u00a0<\/span><\/strong><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Boehringer Ingelheim has an established presence in Switzerland and collaborates with several <\/span><span>other <\/span><span>biotech <\/span><span>companies<\/span><span>, including T3 Pharmaceuticals and Sabia Animal Health<\/span><span>. <\/span><span>Unlike traditional acquisitions,<\/span><span> <\/span><span>Boehringer Ingelheim<\/span><span> maintains the <\/span><span>agile<\/span><span> <\/span><span>structure and entrepreneurial spirit of these <\/span><span>biotech<\/span><span> companies<\/span><span>,<\/span><span> <\/span><span>while providing them with access to <\/span><span>additional<\/span><span> resources, <\/span><span>expertise<\/span><span>, and a broad network of <\/span><span>Boehringer <\/span><span>scientists. This approach fosters synergies<\/span><span> <\/span><span>and enables<\/span><span> the<\/span><span>se<\/span><span> <\/span><span>companies<\/span><span> <\/span><span>to thrive within Boehringer Ingelheims global ecosystem<\/span><span>, <\/span><span>while contributing to the companys commitment to improving patients lives through innovation.\u00a0<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>###<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>About <\/span><span>NBE <\/span><span>Therapeutics<\/span><\/span><span>\u00a0<\/span><\/strong><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"none\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>NBE <\/span><span>Therapeutics, founded in 2012<\/span><span> and <\/span><span>acquired<\/span><span> by Boehringer Ingelheim in 2020, <\/span><span>headquartered in Basel, Switzerland, <\/span><span>is<\/span><span> a renowned biotechnology company at the forefront of developing next-generation antibody drug conjugate (ADC) products for cancer treatment. Committed to scientific excellence and innovation, <\/span><span>NBE <\/span><span>Therapeutics is dedicated to revolutionizing the field of oncology therapeutics by providing precise <\/span><span>and <\/span><span>effective<\/span><span> <\/span><span>treatment options. Leveraging <\/span><span>cutting-edge<\/span><span>, in-house <\/span><span>developed technologies, <\/span><span>NBE <\/span><span>Therapeutics has successfully <\/span><span>established<\/span><span> a groundbreaking platform for antibody-drug conjugates<\/span><span> (ADCs)<\/span><span>, specifically designed to target solid tumors.\u00a0<\/span><\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span> <\/span><\/span><span data-contrast=\"none\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>F<\/span><span>or more information about <\/span><span>NBE <\/span><span>Therapeutics<\/span><span> visit the website<\/span><span> www.nbe-therapeutics.com<\/span><span>.<\/span><\/span><span>\u00a0<\/span><strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span \/><\/span><\/strong><\/p>\n<\/div>\n<div \/>\n<div>\n<div>\n<p><strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Boehringer Ingelheim<\/span><\/span><\/strong><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industrys top investors in research and development, the company focuses on developing innovative therapies that can improve and extend livesin areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain.Our approximately 54,500 employees serve over 130markets tobuild a healthier and more sustainable tomorrow. Learn more at<\/span><\/span><span data-contrast=\"auto\" xml:lang=\"DE-DE\" lang=\"DE-DE\"><span><\/span><\/span><a href=\"https:\/\/www.boehringer-ingelheim.com\/disclaimer\/external?path=http%3A%2F%2Fwww.boehringer-ingelheim.com%2F\" target=\"_blank\" rel=\"noreferrer noopener\" data-mce-href=\"https:\/\/www.boehringer-ingelheim.com\/disclaimer\/external?path=http%3A%2F%2Fwww.boehringer-ingelheim.com%2F\"><span data-contrast=\"none\" xml:lang=\"DE-DE\" lang=\"DE-DE\"><span data-ccp-charstyle=\"Hyperlink\">www.boehringer-ingelheim.com<\/span><\/span><\/a><span data-contrast=\"auto\" xml:lang=\"DE-DE\" lang=\"DE-DE\"><span>.<\/span><\/span><span data-contrast=\"auto\" xml:lang=\"DE-DE\" lang=\"DE-DE\"><span><\/span><\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span><\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<\/div>\n<p><img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3Nzk2NiM0MDIxMDcyODEjMjIwNTExMQ==\" \/> <br \/><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/OWQ0ZDI0MzQtNWU2ZS00OGY1LTk4NGItZmI5ZjNmNTBlYWM3LTEyMTY2NjQtMjAyNS0wNC0wMy1lbg==\/tiny\/Boehringer-Ingelheim-Limited.png\" \/><br \/>\n<a href=\"https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/f121dfae-77e7-4a01-b1ef-6b757767ddab\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/f121dfae-77e7-4a01-b1ef-6b757767ddab\/small\/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png\" border=\"0\" width=\"150\" height=\"46\" alt=\"Primary Logo\" \/><\/a><\/p>\n<p>A <b>OESP<\/b> nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da <b>OESP<\/b> e sao de inteira responsabilidade da <b>GlobeNewswire<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"CHF 27 million investment significantly bolsters Boehringer&#8217;s ADC portfolio, driven by its subsidi","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[34],"tags":[],"class_list":["post-109002","post","type-post","status-publish","format-standard","hentry","category-releases-geral"],"acf":[],"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/109002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=109002"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/109002\/revisions"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=109002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=109002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=109002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}